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Summary
. Data regarding the urea reduction ratio (URR) were
available for analysis from 63 renal centres and 74%
of the prevalent haemodialysis (HD) population in
the UK.
. Fifty-one centres provided URR data on more than
90% of prevalent HD patients.
. The proportion of patients in the UK who met the
Renal Association (RA) clinical practice guideline
for URR (.65%) has been stable between 88–89%
since 2011.
. The median URR has been stable over the same
period (75%).
. There was persistent variation observed between
centres, 15 centres attaining the RA clinical practice
guideline in.90% of patients and 42 centres attain-
ing the guideline in 70–90% of patients.
. Over 95% of the prevalent HD population received
dialysis three times a week but 26% did less than
four hours per session.
. Median URR was similar between patients irrespec-
tive of dialysis session duration.
Fax +41 61 306 12 34
E-Mail karger@karger.com
www.karger.com/nef
# 2018 The UK Renal Registry
Published by S. Karger AG, Basel
This article is licensed under the Creative Commons Attribution-
NonCommercial-NoDerivatives 4.0 International License (CC BY-
NC-ND) (http://www.karger.com/Services/OpenAccessLicense).
Usage and distribution for commercial purposes as well as any
distribution of modified material requires written permission.
Rhodri Pyart
UK Renal Registry, Southmead Hospital, Southmead Road,




Published online: July 11, 2018
Introduction
Measures of dialyser urea clearance have been the
basis for assessing dialysis adequacy since the National
Co-operative Dialysis Study (NCDS) [1]. Observational
studies have shown that the minimum amount of dialysis
a patient receives affects mortality although higher urea
clearance targets in randomised clinical trials have not
been shown to improve survival [2–4]. Of the two com-
monly used measures of dialyser urea clearance, the UK
Renal Registry (UKRR) has historically reported the
urea reduction ratio (URR), the percentage fall in serum
urea following a mid-week dialysis session. Whilst the
alternative Kt/V is a better method for measuring dialysis
dose because it takes account of the size of a patient and
urea removal by ultraﬁltration, it requires data items not
routinely collected by all UK renal centres [5–6]. URR is
the most commonly used measure of urea clearance in
dialysis centres in Europe in daily practice [7] and predicts
minimum dialysis dose in the majority of patients consist-
ently with Kt/V [8]. Both measures can be inﬂuenced by
failure to adhere to standardised sampling techniques
and by urea rebound at the end of dialysis [9, 10].
The direct toxicity of urea and the extent to which
dialyser urea clearance reﬂects the removal of other azo-
taemic toxins which may have greater impact on patient
outcomes remains under debate. Increasing use of
alternative dialysis regimens to the paradigm of thrice
weekly short dialysis sessions upon which urea clearance
models were developed may further challenge their
validity as measures of dialysis adequacy in the future
[11]. Despite such uncertainties, measures of urea clear-
ance currently remain the basis for assessing dialysis
adequacy in international guidelines which remain
remarkably uniform in the minimum recommended
amounts of dialyser urea clearance [12–14].
The UK Renal Registry (UKRR) collects data on
patients with established renal failure (ERF) receiving
haemodialysis (HD) from renal centres in England,
Wales and Northern Ireland as well as from Scotland
via the Scottish Renal Registry. This enables UK renal
centres to compare performance to each other, to the
national average and to the attainment of the minimum
dose of HD, as deﬁned by URR, in the Renal Association
(RA) guidelines on dialysis adequacy.
Table 6.1 lists the current Renal Association audit
measures relevant to haemodialysis patients and whether
the audit measure is currently reported in the UKRR
annual report [12]. Updated RA haemodialysis guidelines
are due to be published in 2018.
The RA clinical practice guidelines for HD dose apply
speciﬁcally to patients undergoing thrice weekly HD.
In these patients, it is recommended that blood for
biochemical measurement (including pre-dialysis urea
for URR) should be taken before the mid-week dialysis
session [12].
Table 6.1. Summary of recommended Renal Association audit measures relevant to haemodialysis adequacy
Haemodialysis adequacy RA audit measure
Included in UKRR
annual report? Reason for non-inclusion
The proportion of patients in the main renal centre and its satellite units
who are on twice weekly haemodialysis
Partly Varying levels of reporting
between centres
Cumulative frequency curves of urea reduction ratio measured using a
standard method of post-dialysis sampling




The proportion of patient non-attendances for haemodialysis sessions
and the proportion of dialysis sessions shortened at the patient’s request
No Data not available
The proportion of thrice weekly haemodialysis sessions which have
prescribed treatment times less than four hours
Yes
The proportion of hospital (main and satellite unit) and home
haemodialysis patients who are prescribed more frequent than thrice
weekly haemodialysis
Partly Not for home
haemodialysis patients
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Methods
Seventy renal centres in the UK submitted data electronically
to the UKRR on a quarterly basis. Cambridge renal centre
(Addenbrooke’s) was unable to submit 2015 and 2016 data at
patient level prior to the UKRR closing date for data submission
but provided summary numbers of patients starting RRT by treat-
ment modality. This centre is therefore excluded from most ana-
lyses in this chapter. The majority of UK centres have satellite
units but for the purposes of this study the data from the renal
centres and their associated satellite units were amalgamated.
Data from two groups of patients were analysed. Firstly, analysis
was undertaken using data from the prevalent adult HD patient
population as of 30 September 2016. The UKRR electronically
receive quarterly data extracts with the latest available result for
each quarter, from renal centres in England, Wales and Northern
Ireland (E,W&NI). Data from Scotland were provided by the Scot-
tish Renal Registry (SRR). For this analysis, data for URR were
taken from the 3rd quarter of 2016 unless that data point was miss-
ing in which case data from the 2nd quarter were taken. The preva-
lent population only included patients receivingHDwhowere alive
on September 30 2016. Data from those patients who had died
before that date have not been included in the analysis. The second
analysis involved adult incident patients who had commenced
treatment with HD during 2015. For these patients, analysis was
undertaken using the last recorded URR in the quarter in which
the patient had started dialysis. The incident HD patient cohort
was followed up for one year and the last recordedURR in the quar-
ter after one-year follow-up was used for this analysis.
From 2015, quarterly HD sessional data as speciﬁed in ver-
sion 4.2 of the UKRR renal dataset were increasingly being
returned by many renal centres. It is hoped that in future, the
number of dialysis sessions per week and time per dialysis session
data can be augmented using these data items. Two centres,
London Guys and Stevenage only returned these data items within
the HD sessional data; hence data for these items were fully
retrieved from the HD sessional data. However, the quality of
the sessional data varied across centres and therefore was not
used to augment quarterly data for the remaining centres at this
time.
Data from patients known to be receiving more than or less than
thrice weekly HD were omitted from the analysis for both the
incident and prevalent population. Patients who had missing data
for the number of dialysis sessions per week were assumed to be
dialysing thrice weekly. However, because not all centres report
frequency of HD, it is possible that data from a small number of
patients receiving HD at a different frequency were included in
the analyses. Home HD patients were excluded from the analysis.
Analyses of the data from both groups of patients included the
calculation of the median URR and of the proportion of patients
who had achieved the RA guideline (as outlined below) in each
of the renal centres, the UK countries as well as for the UK as a
whole. The median URR and proportion of patients who achieved
the RA guideline were also calculated separately for males and
females. The number of dialysis sessions per week and the time
per dialysis session is shown by renal centre.
All patients with data were included in the statistical analyses at
a national level, although centres with fewer than ten patients, or
providing less than 50% data completeness were excluded from
the comparison between centres. The number preceding the centre
name in each ﬁgure indicates the percentage of missing data for
that centre.
The UK RA clinical practice guidelines [12] in operation at the
time these data were collected, were as follows:
HD should take place at least three times per week in nearly
all patients. Reduction of dialysis frequency to twice per week
because of insufﬁcient dialysis facilities is unacceptable.
Every patient receiving thrice weekly HD should have
consistently:
. either URR >65%
. or equilibrated Kt/V (eKt/V) of >1.2 (or single pool Kt/V
of > 1.3) calculated from pre- and post-dialysis urea
values, duration of dialysis and weight loss during dialysis.
To achieve a URR above 65% or eKt/V above 1.2 consist-
ently in the vast majority of the HD population clinicians
should aim for a minimum target URR of 70% or minimum
eKt/V of 1.4 in individual patients.
The duration of thrice weekly HD in adult patients with
minimal residual renal function should not be reduced
below 4 hours without careful consideration.
Patients receiving HD twice weekly for reasons of geogra-
phy should receive a higher sessional dose of HD. If this
cannot be achieved, then it should be recognised that there
is a compromise between the practicalities of HD and the
patient’s long-term health.
Measurement of the ‘dose’ or ‘adequacy’ of HD should be
performed monthly in all hospital HD patients and may be
performed less frequently in home HD patients. All dialysis
units should collect and report this data to their regional
network and the UKRR.
Post-dialysis blood samples should be collected either by
the slow-ﬂow method, the simpliﬁed stop-ﬂow method, or
the stop dialysate ﬂow method. The method used should
remain consistent within renal units and should be reported
to the Registry.
The RA clinical practice guidelines for HD dose apply speciﬁ-
cally to patients undergoing thrice weekly HD. In these patients,
it is recommended that blood for biochemical measurement
(including pre-dialysis urea for URR) should be taken before the
mid-week dialysis session [12].
The data were analysed using SAS 9.3.
Results
Data completeness
Sixty three of the 71 UK renal centres submitted HD
dose (URR) data to the UKRR (table 6.2). Data were
available for 73.7% (N = 15,501) of the total prevalent
population (N = 21,041) treated with HD who met the
inclusion criteria for these analyses.
Fifty-one centres reported URR data on more than
90% of their patients. Six centres reported URR data
on less than 50% of prevalent patients (Carshalton,
UK haemodialysis dose Nephron 2018;139(suppl1):151–164 153
Manchester RI, Newcastle, Reading, Shrewsbury, Sunder-
land). URR data were not received from eight centres
(Cambridge, Ipswich, London St Bartholomew’s, London
Kings, London Royal Free, London St Georges, Liverpool
Aintree, Liverpool Royal Inﬁrmary).
There was little change in the overall completeness of
URR data submitted to the UKRR from most centres in
2016 compared with 2015, with an average change of
1.2% (range: −5.4% to 88.4%). Any centre change may
have occurred due to changes in computerised data
bases and data extraction, or by centres moving to on-
line Kt/V, or total Kt/Vurea including residual renal
urea clearance rather than URR as the preferred measure
of haemodialysis dose.
Eleven centres did not provide data on frequency of
dialysis sessions, and 49 centres provided data on
Table 6.2. Percentage completeness of URR data returns for prevalent patients on HD by centre, on 30/9/2016
Centre N % completeness Centre N % completeness
England
B Heart 333 99.7 Sheff 497 94.2
B QEH 884 99.7 Shrew 165 1.2
Basldn 134 96.3 Stevng 399 98.5
Bradfd 214 99.5 Sthend 87 98.9
Brightn 374 99.5 Stoke 279 93.9
Bristol 441 100.0 Sund 199 1.5
Camb 0 0.0 Truro 132 89.4
Carlis 86 100.0 Wirral 146 96.6
Carsh 745 0.3 Wolve 270 88.2
Chelms 110 94.6 York 151 100.0
Colchr 113 92.9
Covnt 338 96.2 N Ireland
Derby 181 99.5 Antrim 111 96.4
Donc 171 95.9 Belfast 161 98.8
Dorset 254 91.7 Newry 69 79.7
Dudley 162 95.7 Ulster 94 100.0
Exeter 396 100.0 West NI 100 100.0
Glouc 222 100.0
Hull 302 99.3 Scotland
Ipswi 122 0.0 Abrdn 186 99.5
Kent 358 98.9 Airdrie 181 97.8
L Barts 952 0.0 D & Gall 39 97.4
L Guys 571 98.1 Dundee 167 98.8
L Kings 521 0.0 Edinb 256 99.2
L Rfree 636 0.0 Glasgw 528 100.0
L St.G 312 0.0 Inverns 76 98.7
L West 1,348 88.4 Klmarnk 111 100.0
Leeds 422 100.0 Krkcldy 131 100.0
Leic 788 99.5
Liv Ain 152 0.0 Wales
Liv Roy 262 0.0 Bangor 59 100.0
M RI 431 2.6 Cardff 429 99.8
Middlbr 293 100.0 Clwyd 66 98.5
Newc 264 23.1 Swanse 310 99.4
Norwch 291 99.0 Wrexm 103 96.1
Nottm 323 91.6
Oxford 379 98.9 England 17,864 69.2
Plymth 121 96.7 N Ireland 535 96.3
Ports 479 99.4 Scotland 1,675 99.3
Prestn 500 81.4 Wales 967 99.2
Redng 280 15.4 UK 21,041 73.7
Salford 274 66.4
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.90% of patients (table 6.3). Eleven centres did not
provide data on dialysis session times, and 45 centres
provided data on .90% of patients (table 6.4). In those
centres not returning data, there appeared to be a
common IT provider and locally collected data was not
received by the UKRR. Ways of overcoming this problem
in the future are being sought.
Of the total incident patient population (N = 4,879)
who started HD during 2015 and meeting the inclusion
criteria for URR analyses, 47.0% (N = 2,298) had URR
data available during the ﬁrst quarter of treatment (data
not shown). This was an increase from 43% in the 2014
incident population. Eight centres did not provide
data for the ﬁrst quarter of treatment, and 41 centres pro-
vided data on .90% of incident patients during the ﬁrst
year.
Achieved URR
The median URR for prevalent HD patients was 75%
but ranged between centres from 69–82% (ﬁgure 6.1a).
There was evidence that the median URR for female
HD patients at 78% (centre range 73–85%) (ﬁgure 6.1b)
was greater than that of male HD patients, with a median
URR at 74% (centre range 68–80%) (ﬁgure 6.1c).
There was evidence that the median sessional URR
was lower for patients aged ,70 years (median 75%)
compared to older patients 570 years (median 76%).
Similarly, the median sessional URR was lower for both
genders in the younger age group (,70 years) compared
to the older age group (570 years of age): median URR
of 77% for females ,70 years of age compared to a
median URR of 78% for female patients aged 570
years. Similarly, for male patients aged ,70 years of
age the median URR of 73% was lower than for male
patients aged 570 years (median URR 74%).
The current UK RA clinical guideline target is to
achieve a minimum sessional URR of 65%, and this
was achieved in 87.5% of HD prevalent patients (centre
range 70.8–95.7%) (ﬁgure 6.2). A higher number of
female patients achieved this minimum target (92.1%,
Table 6.3. Number of dialysis sessions for prevalent patients on HD by centre, on 30/9/2016
%
%
Centre N completeness ,3 sessions 3 sessions .3 sessions
England
B Heart 362 79.0 9.4 89.9 0.7
B QEH 884 0.0
Basldn 149 95.3 1.4 89.4 9.2
Bradfd 222 100.0 3.2 96.4 0.5
Brightn 378 99.5 0.5 98.9 0.5
Bristol 460 100.0 3.5 95.9 0.7
Carlis 88 97.7 2.3 97.7 0.0
Carsh 755 99.7 1.1 98.7 0.3
Chelms 124 100.0 8.9 88.7 2.4
Colchr 113 98.2 0.0 100.0 0.0
Covnt 338 2.1
Derby 181 43.1
Donc 173 98.3 0.6 98.8 0.6
Dorset 259 99.6 1.9 98.1 0.0
Dudley 166 89.2 2.7 97.3 0.0
Exeter 415 99.8 3.9 95.4 0.7
Glouc 222 0.0
Hull 302 0.3
Ipswi 133 100.0 8.3 91.7 0.0
Kent 371 98.9 1.4 96.5 2.2
L Barts 952 0.0
L Guys 600 99.2 3.9 95.1 1.0
L Kings 521 100.0 0.0 100.0 0.0
L Rfree 636 0.0
L St.G 315 97.1 1.0 99.0 0.0
L West 1,365 63.5 1.0 98.0 0.9
Leeds 458 99.6 7.9 92.1 0.0
Leic 796 99.5 1.0 99.0 0.0




Centre N completeness ,3 sessions 3 sessions .3 sessions
Liv Ain 155 99.4 0.6 98.1 1.3
Liv Roy 306 97.4 0.3 85.2 14.4
M RI 436 35.3
Middlbr 294 23.5
Newc 271 100.0 1.1 97.4 1.5
Norwch 298 99.7 1.0 97.6 1.3
Nottm 344 99.7 0.6 93.9 5.5
Oxford 379 100.0 0.0 100.0 0.0
Plymth 121 0.0
Ports 523 99.0 5.0 91.5 3.5
Prestn 500 0.0
Redng 280 97.9 0.0 100.0 0.0
Salford 329 99.7 1.5 83.2 15.2
Sheff 514 99.8 3.3 96.7 0.0
Shrew 174 100.0 3.4 94.8 1.7
Stevng 466 99.2 13.0 85.5 1.5
Sthend 107 99.1 18.9 81.1 0.0
Stoke 290 98.3 2.1 96.1 1.8
Sund 216 100.0 0.9 92.1 6.9
Truro 145 91.0 6.8 90.2 3.0
Wirral 165 97.0 0.6 88.1 11.3
Wolve 270 7.0
York 161 85.7 0.0 92.8 7.2
N Ireland
Antrim 111 96.4 0.0 100.0 0.0
Belfast 164 98.2 0.6 98.1 1.2
Newry 76 100.0 9.2 90.8 0.0
Ulster 99 100.0 3.0 94.9 2.0
West NI 111 99.1 1.8 90.0 8.2
Scotland
Abrdn 204 98.0 1.5 91.0 7.5
Airdrie 182 91.2 0.6 99.4 0.0
D & Gall 45 95.6 2.3 86.0 11.6
Dundee 172 97.7 0.0 97.0 3.0
Edinb 261 92.7 0.8 97.9 1.2
Glasgw 534 93.6 0.4 98.8 0.8
Inverns 80 98.8 1.3 94.9 3.8
Klmarnk 113 94.7 0.0 98.1 1.9







England 18,482 70.2 2.8 95.2 2.0
N Ireland 561 98.6 2.4 95.3 2.4
Scotland 1,726 94.7 0.7 96.9 2.4
Wales 967 0.0 0.0 0.0 0.0
UK 21,736 69.7 2.6 95.4 2.0
Blank cells denote no data returned by the centre or ,10 patients in the renal centre or data completeness was ,50%
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Table 6.4. Time per dialysis session for prevalent patients on HD by centre, on 30/9/2016
%
% per dialysis session
Centre N completeness ,4 hours 4–5 hours .5 hours
England
B Heart 333 77.8 14.3 85.7 0.0
B QEH 884 0.0
Basldn 134 94.8 37.0 63.0 0.0
Bradfd 214 99.1 25.9 74.1 0.0
Brightn 374 97.9 7.1 92.9 0.0
Bristol 441 100.0 24.0 76.0 0.0
Carlis 86 97.7 8.3 91.7 0.0
Carsh 745 98.5 11.2 88.4 0.4
Chelms 110 100.0 40.0 60.0 0.0
Colchr 113 98.2 0.9 99.1 0.0
Covnt 338 3.6
Derby 181 43.1
Donc 171 98.3 24.4 75.6 0.0
Dorset 254 100.0 8.7 91.3 0.0
Dudley 162 88.9 14.6 85.4 0.0
Exeter 396 100.0 51.0 49.0 0.0
Glouc 222 0.0
Hull 302 1.3
Ipswi 122 100.0 10.7 89.3 0.0
Kent 358 99.7 56.6 43.4 0.0
L Barts 952 0.0
L Guys 571 99.1 30.9 68.9 0.2
L Kings 521 100.0 39.0 61.0 0.0
L Rfree 636 0.0
L St.G 312 87.5 4.4 95.6 0.0
L West 1,348 63.5 18.5 79.6 2.0
Leeds 422 100.0 20.9 79.1 0.0
Leic 788 78.3 9.9 86.7 3.4
Liv Ain 152 100.0 21.7 78.3 0.0
Liv Roy 262 99.2 8.5 91.2 0.4
M RI 431 34.6
Middlbr 293 100.0 38.6 61.4 0.0
Newc 264 100.0 18.6 79.9 1.5
Norwch 291 99.7 58.3 41.7 0.0
Nottm 323 99.7 6.2 93.8 0.0




Redng 280 96.8 19.9 80.1 0.0
Salford 274 95.3 13.4 86.6 0.0
Sheff 497 88.7 84.8 15.0 0.2
Shrew 165 100.0 44.8 55.2 0.0
Stevng 399 99.5 81.4 18.6 0.0
Sthend 87 98.9 48.8 51.2 0.0
Stoke 279 100.0 11.8 88.2 0.0
Sund 199 83.9 21.6 78.4 0.0
Truro 132 97.0 65.6 33.6 0.8
Wirral 146 100.0 25.3 74.0 0.7
Wolve 270 7.0
York 151 85.4 10.9 89.1 0.0
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centre range 76.0–100.0%) compared to male patients
(84.6%, centre range 67.5–95.3%).
Changes in URR over time
From 2002 there was an initial progressive increase in
the percentage of patients achieving the current RA
clinical practice guidelines (URR .65%) until 2011,
after which it has plateaued around 88% (ﬁgure 6.3).
Similarly, the median URR in UK haemodialysis patients
rose from 71% to stabilise at 75% since 2011.
Variation of achieved URR with time on dialysis
The proportion of patients who attained the UK RA
clinical guideline for URR was greater for those who
had been treated by haemodialysis for two years or
longer compared to those who had been dialysing for
,6 months (ﬁgure 6.4). For all strata of dialysis vintage,
marked improvement in the proportion of patients
receiving the sessional target dose of haemodialysis has
plateaued in recent years.
Changes in URR for incident patients
The median sessional URR during the ﬁrst quarter
after starting haemodialysis treatment in the UK was
67.0% (centre range 58.5–76.0%) (ﬁgure 6.5a) for inci-
dent HD patients in 2015. At the end of one-year
follow-up, the median URR had increased to 73.0%
(centre range 68.0–83.0%) (ﬁgure 6.5b). More centres
are included in the analysis this year due to the threshold
for centre inclusion being relaxed to include centres
returning data for at least ten patients rather than a
minimum of 20 patients.
There was evidence that the median sessional URR
during the ﬁrst three months after starting haemodialysis
Table 6.4. Continued
%
% per dialysis session
Centre N completeness ,4 hours 4–5 hours .5 hours
N Ireland
Antrim 111 97.3 14.8 85.2 0.0
Belfast 161 100.0 16.8 83.2 0.0
Newry 69 100.0 52.2 47.8 0.0
Ulster 94 100.0 12.8 87.2 0.0
West NI 100 99.0 58.6 41.4 0.0
Scotland
Abrdn 186 98.4 5.5 92.3 2.2
Airdrie 181 98.9 13.4 83.8 2.8
D & Gall 39 100.0 20.5 79.5 0.0
Dundee 167 97.6 7.4 92.0 0.6
Edinb 256 92.6 38.4 61.6 0.0
Glasgw 528 99.4 6.5 89.1 4.4
Inverns 76 98.7 17.3 82.7 0.0
Klmarnk 111 92.8 0.0 93.2 6.8







England 17,864 66.2 27.5 72.1 0.4
N Ireland 535 99.3 28.1 71.9 0.0
Scotland 1,675 97.3 13.9 83.7 2.5
Wales 967 0.0
UK 21,041 66.5 25.9 73.4 0.7
Blank cells denote no data returned by the centre or ,10 patients in the renal centre or data completeness was ,50%




























































































































































































































































































































































































































































































































































































































































































































































































































































































































































Fig. 6.1a. Median URR achieved in prevalent patients on HD by centre, 30/9/2016
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Fig. 6.3. Change in the percentage of
prevalent patients on HD with URR .65%














































































































































































































































































































UCL N = 15,501
% with URR >65%
LCL
UK mean
Fig. 6.2. Percentage of prevalent patients on HD with URR .65% by centre, 30/9/2016





























Fig. 6.4. Percentage of prevalent patients
on HD achieving URR .65% by time on
RRT between 2002 and 2016
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was lower for patients aged ,70 years (median URR
66.0%) compared to patients older than 570 years
(median URR 69.0%). Similarly, at the end of the ﬁrst
year of haemodialysis the median sessional URR was
again lower for patients aged ,70 years (median URR
73.0%) versus570 years of age (median URR 74.0%).
Haemodialysis session duration for prevalent
HD patients
For those centres which returned data, the majority of
prevalent patients (73.4%) dialysed between 4–5 hours,
with 25.9% dialysing less than four hours per session,
and only 0.7% dialysing for more than ﬁve hours
(table 6.4). However, there were marked differences
between centres, with between 1–85% of patients reported
to be dialysing less than four hours. Median URR was
similar for patients dialysing longer (54 hours) versus
shorter dialysis sessions (,4 hours).
Haemodialysis session frequency for prevalent
HD patients
Dialysis frequency data were available for 69.7% of
patients (table 6.3) in 2016 compared with 68.7% in
2015. Although 95.4% of all prevalent haemodialysis
patients dialysed thrice weekly, there were marked differ-
ences in centre practices. Centres reported dialysing
between 0.0–18.9% of patients twice weekly or less, and










































































































































































































































































































































































































































































































































UK median N = 2,455
Fig. 6.5b. Median URR one year after starting RRT for incident patients who started HD in 2015
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reported dialysing .10% of patients less than thrice
weekly and four centres more often than thrice weekly.
The sessional URR was lower with lower dialysis fre-
quency (median URR 71.6% for prevalent HD patients
dialysing ,3 times per week versus a median URR of
75.0% for patients dialysing53 times per week).
Discussion
Haemodialysis is a life-sustaining treatment for
patients with end stage kidney disease. In addition to
the clearance of azotaemic toxins, the dialysis prescrip-
tion encompasses volume control, maintenance of acid-
base status and mono- and di-valent ion homeostasis.
Dialysis adequacy is deﬁned in the current RA and inter-
national clinical guidelines by dialyser urea clearance.
Target dialyser urea clearance of 70% is recommended
to consistently achieve the minimum URR of .65%
in as many patients as possible [12–14]. A minimum
dialysis adequacy appears to be necessary for patient well-
being [1], but the beneﬁts of higher clearance and the
optimal dialysis dose have not been well deﬁned [2–5].
The older, more comorbid demographic of the current
dialysis cohort may differ from previously studied popu-
lations although UKRR data has consistently, somewhat
paradoxically, shown higher sessional urea clearance
amongst older patients [15–17]. Muscle mass declines
with age [15], and dialysis patients with less muscle
mass are less physically active [16] and have lower energy
expenditure [17]. So, one may have expected higher
dialyser urea clearances delivered to the younger rather
than older patients [18]. This apparent greater dialyser
urea clearance in the older patient may be due to a math-
ematical confounder, in that it is easier to achieve a
higher percentage urea clearance in a smaller patient
with a lower pre-dialysis serum urea concentration com-
pared to that in a heavier patient with a higher starting
urea [19], and this confounder not only affects urea
reduction ratio, but also Kt/Vurea [20, 21]. As there is
an association between muscle mass and body surface
area, then as Kt/Vurea underestimates clearance in
patients with increased body mass index, and overesti-
mates clearance in those with smaller body mass index
[22], an adjustment for body surface area or energy
expenditure may be more appropriate [18, 23].
Men and women differ in size, body composition and in
their rates of resting energy expenditure all of which can
contribute to lower dialyser urea clearance being needed
in women to achieve a higher URR [16, 18]. Observational
studies and post hoc analyses of the HEMO study have
suggested that women may beneﬁt from a greater dialyser
urea clearance than men [24, 25], and for the same urea
dialyser clearance women would receive a lower effective
clearance [20]. However, neither UK RA nor other clinical
guidelines advocate different targets based on gender [12].
It is therefore reassuring that in the UK, the median
sessional URR remained higher for women than men to
prevent lower dialysis dosing [20].
Following increases in the proportion of UK haemo-
dialysis patients achieving target URR from 2002 until
2010, this has since stabilized around 88% for the preva-
lent population. Standardised sampling technique and
improved haemodialysis technology may have contribu-
ted to the earlier improvement [26]. The subsequent
plateau in target attainment likely reﬂects the reality
that not all established dialysis patients will consistently
achieve the target URR, for example due to poorly func-
tioning vascular access, cardiovascular intolerance on the
day of urea sampling, or patients receiving palliative
dialysis [21]. However, the marked inter-centre variabil-
ity in the proportion of patients achieving the URR
minimum of.65%, ranging from 70.7–95.7% of patients
suggests a centre practice effect. Our current analysis
makes no adjustment for centre differences in terms of
patient case-mix, patient non-adherence to dialysis
session length or practice differences such as high ﬂux
dialysis or haemodiaﬁltration. Residual renal function is
not accounted for in the URR calculation and centre
practice differences around early versus delayed start
dialysis as well as whether centres practice an incremental
approach to initiating dialysis may account for some of
the differences observed [27]. The effect of residual
renal function most likely accounts for the increase in
URR observed in the incident haemodialysis patients
from the ﬁrst quarter to the ﬁnal quarter URR returns,
as shown by one centre increasing from ,60% to .70%.
In the UK, centres receive sessional payments, initially
introduced to encourage more frequent dialysis.
However, only some 2% of patients dialysing in England
were reported to dialyse more than thrice weekly
although there was variation between centres, as four
centres reported dialysing over 10% of their patients
more frequently. The UK Renal Association clinical
guidelines recommend that patients should have thrice
weekly dialysis [12], and although on average only
around 3% of patients dialysed twice or less frequently,
again practice varied markedly with centres reporting a
range of 0% to 19%. The UKRR were unable to determine
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whether this was due to patient-case mix, centres taking
into account residual renal function, or resource limit-
ations; although on enquiry to individual centres it
would appear to be a combination of patient-case mix
[21], centres measuring residual renal function and
practicing incremental dialysis [27].
The UK Renal Association clinical guidelines recom-
mend that patients without residual renal function
should dialyse for four hours [12]. Most prevalent
patients dialysed between 4–5 hours, however over a
quarter (25.9%) dialysed for shorter times (,4 hours)
and less than 1% dialysing for longer (.5 hours). Further
marked inter-centre variability was noted in session
duration with a wide range (0.0–84.8%) of patients dia-
lysing for less than four hours. Twenty six of the 53
centres that provided data on time dialysed (49%), dia-
lysed more than 20% of patients for,4 hours. The guide-
lines date from a time when low-ﬂux dialysers were the
standard, and prior to the improvements in dialyser tech-
nology and introduction of other modalities such as
haemodiaﬁltration [26]. However, although greater urea
clearance can potentially be achieved with shorter session
times, this does not imply that other azotaemic toxins
[28–31], as well as sodium would be equally cleared
[32]. Once again, the UKRR were unable to determine
whether centres with higher proportions of patients
having shorter dialysis sessions was due to patient case-
mix, patient wishes, intolerance of dialysis, or clinician
factors, including considering residual renal function.
The pros and cons of using URR as a measure of
dialysis adequacy continue to be debated [11, 21, 30,
31]. It does not account for the clearance of other larger
molecules, nor does it reﬂect other important aspects of
dialysis such as session length, volume control, sodium
balance and the correction of metabolic acidosis all of
which can potentially impact patient outcomes [29, 32].
However, no consensus has yet emerged on alternative
markers of HD adequacy [33]. Practically, URR has
been relatively simple to collect and the resulting data
completeness has made it the easier to analyse for the
UKRR.
It is planned to work with centres to ensure dialysis
session data can be used to augment the overall data
completeness. As data collection expands, Kt/V and
dialysis prescription practice will be used to improve
the analysis.
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